Skip to Content
Merck
CN

E1400000

Erythromycin estolate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Erythromycin 2′-propionate dodecyl sulfate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
C40H71NO14 · C12H26SO4
CAS Number:
3521-62-8
Molecular Weight:
1056.39
NACRES:
NA.24
PubChem Substance ID:
329799009
UNSPSC Code:
41116107
MDL number:
MFCD00084691

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C37H67NO13.C12H26O4S/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-12H2,1H3,(H,13,14,15)/t18-,19+,20?,21+,22-,23-,24-,25?,26-,28+,29+,30+,31-,32-,34-,35-,36+,37+;/m0./s1

SMILES string

CCCCCCCCCCCCOS(O)(=O)=O.CC[C@H]1OC(=O)[C@@H](C)[C@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@](C)(O)C[C@H](C)C(=O)C(C)[C@@H](O)[C@@]1(C)O

InChI key

SKDGGFHGLZBNBC-CAHOBLCESA-N

grade

pharmaceutical primary standard

API family

erythromycin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Erythromycin estolate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 3

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Is erythromycin indicated in pregnancy?
D Hillyer
RN, 55(5), 11-11 (1992-05-01)
D Adam et al.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 15(9), 712-717 (1996-09-01)
In a randomized, prospective, multicenter trial, 227 children ranging in age from 3 to 17 years who had tonsillopharyngitis and a throat culture positive for group A beta-hemolytic streptococci (GABHS) were treated with erythromycin estolate (40 mg/kg/d in two divided
L W Snellman et al.
Pediatrics, 91(6), 1166-1170 (1993-06-01)
To determine if it is appropriate to recommend that patients with group A beta-hemolytic streptococcal pharyngitis, who are clinically well by the morning after starting antibiotic treatment, can return to school or day care, or if they should wait until
N Thibault et al.
Journal of hepatology, 19(3), 367-376 (1993-11-01)
The mechanism of the protective effect of ursodeoxycholic acid in cholestatic liver diseases remains unclear. Since there is evidence that alterations in the pericanalicular actin microfilament network play a major role in cholestasis, the aims of this study were (a)
Soo-Jin Park et al.
Journal of colloid and interface science, 271(2), 336-341 (2004-02-20)
In this work, the producing of a biodegradable poly(l-lactide) (PLA)/poly(ethylene glycol) (PEG) microcapsule by emulsion solvent evaporation method was investigated. The effect of PEG segments added to the PLA microcapsules on the degradation, size distribution, and release behavior was studied.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service